Paul Saenger
Pediatric Endocrinology · Mineola, NYNPI 1275695298
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $112,949 of the $179,587 with a category attached, or 62.9%. 9 manufacturers reported payments, led by Novo Nordisk at 54.5% of the total. Reporting peaked in 2022 at $61,220 and has fallen 73.9% since, to $15,986 in 2025. Among pediatric endocrinology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $736.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$98K
- Biomarin Pharmaceutical Inc.$39K
- Pfizer$20K
- Ascendis Pharma Endocrinology Inc$19K
- Novo Nordisk Health Care AG$2K
- Novo Nordisk AS$1K
- plus $258 from 3 others
Across 1,220 payments — averaging $713.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$610K
- Biomarin Pharmaceutical Inc.$83K
- Pfizer$68K
- Ascendis Pharma Endocrinology Inc$56K
- OPKO Pharmaceuticals, LLC$53K
What the payments were for
- Consulting fees$24,54414%
- Speaking & faculty fees$112,94963%
- Travel & lodging$34,94719%
- Food & beverage$6,9844%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 115 | $97,942 |
| Biomarin Pharmaceutical Inc. | 65 | $38,664 |
| Pfizer | 23 | $20,310 |
| Ascendis Pharma Endocrinology Inc | 20 | $19,098 |
| Novo Nordisk Health Care AG | 13 | $1,889 |
| Novo Nordisk AS | 4 | $1,427 |
| Soleno Therapeutics, Inc. | 2 | $208 |
| Hexal AG | 1 | $32 |
| AbbVie | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$71,915
- Sogroya$23,037
- VOXZOGO 1.2mg$21,595
- NGENLA$19,194
- SKYTROFA$17,540
- VOXZOGO$5,528
- GENOTROPIN$920
- VYKAT XR$150
How this compares
$179,587 in reported general payments places this provider in the 95th percentile of 138 pediatric endocrinology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alendronate Sodium | 11 | $266 |
| Levothyroxine Sodium | 12 | $235 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in Mineola
- Moris AnguloMineola$73K
- Robert LevineMineola$33K
- Siham AccachaMineola$23K
- Mariano Castro-MaganaMineola$18K
- Julia Barillas CerritosMineola$6K
- Alicia RomanoSleepy Hollow$157K
- Svetlana TenStaten Island$101K
- Robert RapaportNew York$98K
- Jill BrodskyPoughkeepsie$45K
- Jorge Mejia-CorlettoNorth Babylon$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.